IRADIMED (IRMD) Aandelenoverzicht
IRADIMED CORPORATION ontwikkelt, produceert, verkoopt en distribueert MRI-compatibele intraveneuze infuuspompsystemen en MRI-compatibele bewakingssystemen voor vitale functies van patiënten en bijbehorende accessoires. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 2/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor IRMD uit onze risicocontroles.
IRMD Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IRADIMED CORPORATION Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$93.17 |
| 52 Week Hoogtepunt | US$107.90 |
| 52 Week Laag | US$50.88 |
| Bèta | 0.91 |
| 1 maand verandering | 4.47% |
| 3 maanden verandering | -10.03% |
| 1 Jaar Verandering | 78.21% |
| 3 jaar verandering | 93.06% |
| 5 jaar verandering | 232.63% |
| Verandering sinds IPO | 841.11% |
Recent nieuws en updates
Narratiefupdate • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Narratiefupdate • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Recent updates
Narratiefupdate • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Narratiefupdate • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Narratiefupdate • Mar 26
IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.Narratiefupdate • Mar 11
IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.Narratiefupdate • Feb 25
IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.Narratiefupdate • Feb 10
IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.Narratiefupdate • Jan 27
IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.Narratiefupdate • Jan 12
IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.Narratiefupdate • Dec 14
IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.Narratiefupdate • Nov 29
IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.Narratiefupdate • Nov 15
IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.Narratiefupdate • Nov 01
IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Analyseartikel • Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...Analyseartikel • Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Analyseartikel • Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Nieuw narratief • Sep 24
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.Analyseartikel • Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...Analyseartikel • Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analyseartikel • Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Analyseartikel • Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...Analyseartikel • Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Seeking Alpha • Oct 10
Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y
Iradimed (NASDAQ:IRMD) said it withdrew its 510(K) application seeking U.S. Food and Drug Administration (FDA) approval of its next-generation intravenous (IV) infusion pump system, MRidium 3870; and reported preliminary results for Q3. "The FDA requested additional information that was not feasible to provide within FDA's review deadline; therefore, we decided to withdraw our application to provide us more time to understand and resolve the FDA’s concerns," said Iradimed President and CEO Roger Susi in an Oct. 10 press release. In addition, Iradimed noted that Q3 revenue is expected to be ~$13.4M, up 23% Y/Y as per preliminary results. Consensus Revenue Estimate for Q3 (one analyst) is $13.17M. "These third quarter preliminary results represent our highest revenue quarter," Susi noted. "Orders booked in the quarter exceeded our shipments as we continue to add to our extensive backlog. Domestic unit orders booked in the quarter for our current MRidium 3860 Infusion Pump System were the highest over the last three years, demonstrating the continued strong demand for this product." The company develops Magnetic Resonance Imaging (MRI)-compatible medical devices.Seeking Alpha • Aug 23
IRadimed: Record Revenue Could Translate To Share Price Appreciation
The share price declined due to a sales slowdown during the height of the pandemic. The company has reported record revenues for the past three consecutive quarters. The stock sold off in 2019 due to regulatory concerns, but the company continued to report record revenues. The stock price bounced back to reach new highs in 2019, and all signs are that history will repeat itself as the fundamental picture remains sound. IRadimed (IRMD) develops, markets, and distributes non-magnetic Medical Resonance Imaging ("MRI") compatible medical devices, accessories, and related services. IRMD is a profitable company that is enjoying increasing demand for its products and is exploiting the opportunity by adding new products. The company has a monopoly as there aren't any direct competitors and it is unlikely that any will come about. No one else is marketing an FDA-approved non-magnetic, MRI-compatible medical device. The recent stock price decline is offering an excellent opportunity to initiate a position or to add shares for an investor interested in a growth stock. My investment thesis: The company is reporting record revenues that exceed the pre-covid time period, but the share price is still 65% below the high. I believe the stock price will follow the strong fundamental picture. I first wrote about the company in 2019 as I saw a disconnect between the stock's fundamentals and the technicals. IRMD was on its third consecutive quarter of record revenues but the stock price had declined about 50%. History is repeating itself for IRMD as the company has again recorded three consecutive quarters of record revenues but the stock price hasn't responded in kind. A comparison of the 2019 and the present charts illustrate similar technical pictures. Despite the reason sell-off the stock price is nearly double now from when my first article was published. I'll follow the technical illustration with a look at the fundamentals which support the stock price resuming its pre-covid uptrend. 2019 chart 2019 chart (Y CHARTS) Present chart IRMD data by YCharts The stock is off 65% from its high of $56/share. The fundamentals point to the stock price climbing back up and reaching new highs. Earnings The company recently reported second-quarter revenue of $12.7 million, nearly a 30% increase over the second quarter of last year, and earnings of $0.26, 116% higher than for the same period in the prior year. It was also reported that bookings were at record levels, setting up continued revenue growth going forward. Management provided guidance of revenue of $13.1 million to $13.3 million for the third quarter and for the full 2022 revenue of $52.5 million to $53.2 million, about 27% higher than for the previous year and higher than pre-covid revenue. Revenues for 2023 could top $70 million if the company continues growing at the same pace. It's possible that the growth rate could accelerate as the company has increased its sales staff and introduced a new product. Share info and valuation There are about 12 million shares. Institutions own about half while insiders own about 43% of the shares. The market cap is $447 million. The company last reported $2.35 million in debt and $52.16 million in cash resulting in an EV of $397 million. The company has sufficient funds to maintain its operations and also make an acquisition if management so desires. IRMD trades at high multiples at first glance but not so when compared to its peer group. IRMD enjoys better margins and therefore the higher P/S and P/B ratios are justified. There's also a premium that IRMD stock can command as the company is a virtual monopoly. IRMD Med. Device Ind. Gross Margin 76% 54% Ebit Margin 26% 16% Price to Sales 6.25 4.04 Price to Book 6.77 4.37 Price to Earnings 35.0 55.39 Compiled by the author from data from CSI Markets Moat The stock price drop in 2019 was due to regulatory compliance issues in Europe and in the U.S. The European Union equivalent of the U.S. FDA found a technical non-conformity with the IRMD MRI compatible patient vital signs monitor. The company received a warning letter from the FDA in 2014 pursuant to a routine inspection that identified eight areas of concern. The warning letter had not been closed until October 2019 and the issue clouded IRMD's future and cast doubt on investors. A great indicator of IRMD's dominance is that Bayer (BAYZF) now offers IRMD non-metallic, MRI-compatible products on its website after stopping production of its own non-magnetic, MRI-compatible devices due to many recalls and FDA warnings. The only other previous IRMD competitor that I could find was Nebion which was also unable to overcome FDA recalls. The Bayer and Nebion experiences and the regulatory hurdles that IRMD has had to clear, point out the difficulties in maintaining regulatory compliance and serve as a moat. A new company seeking to enter IRMD's space would need at least three years to gain FDA clearance. Products The flagship product is a non-magnetic MRI-compatible MRI pump, the MRidium 3860, which serves patients too ill to be taken off intravenous medication and young children who require medication in order to remain still during a scan. The 3860 was FDA approved in 2009. MRidium 3860 (IRadimed website) The FDA approved the company's second commercial device, a non-magnetic MRI-compliant patient monitor system in 2017, the IRadimed 3880. This device is the only portable MRI-compatible patient vital sign monitor allowing for patient monitoring as the patient is moved throughout the hospital. Pumps are the bread and butter of IRMD's business. The monitor is bundled with the pump and offered as a more complete solution. IRadimed The company also offers disposable components, various available upgrades to meet customer needs, and offers extended maintenance contracts. The disposable components and maintenance products provide recurring revenue. The company does not break out what percentage of revenue is recurring. I estimate it to be about 25% of total revenue. A third product, a magnetic detection device has had a delayed introduction due to the pandemic, but sales began this quarter. This device is designed for placement at the entrance to MRI rooms to ensure that magnetic material is detected before it is allowed to enter the room. For anyone not familiar with what happens with magnetic material during an MRI scan please click here. IRadimedRendement voor aandeelhouders
| IRMD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 7.2% | 4.0% | -0.3% |
| 1Y | 78.2% | -18.6% | 26.7% |
Rendement versus industrie: IRMD overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -18.6 % opleverde.
Rendement versus markt: IRMD overtrof de US markt, die het afgelopen jaar een rendement opleverde van 26.7 %.
Prijsvolatiliteit
| IRMD volatility | |
|---|---|
| IRMD Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: IRMD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van IRMD is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1992 | 166 | Roger Susi | www.iradimed.com |
IRADIMED CORPORATION ontwikkelt, produceert, verkoopt en distribueert MRI-compatibele intraveneuze infuuspompsystemen en MRI-compatibele bewakingssystemen voor patiënt vitale functies en bijbehorende accessoires. Het bedrijf biedt MRidium 3870 en 3860+ MRI-compatibele intraveneuze infuuspompsystemen met bijbehorende wegwerp IV-slangensets; 3880 MRI-compatibel bewakingssysteem voor vitale functies van de patiënt; en 3600 FMD1 met externe alarmregistratie-eenheid ferromagnetisch detectieapparaat. Het bedrijf levert ook niet-magnetische infuuspalen, draadloze displays/bedieningen op afstand, zijwaartse pompmodules, systemen voor reductie van doseringsfouten en SpO2-monitoring met sensoren en accessoires.
IRADIMED CORPORATION Samenvatting
| IRMD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.16b |
| Inkomsten(TTM) | US$23.61m |
| Inkomsten(TTM) | US$86.28m |
50.4x
Koers/Winstverhouding13.8x
P/S-verhoudingIs IRMD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| IRMD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$86.28m |
| Kosten van inkomsten | US$19.99m |
| Brutowinst | US$66.30m |
| Overige uitgaven | US$42.68m |
| Inkomsten | US$23.61m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.85 |
| Brutomarge | 76.84% |
| Nettowinstmarge | 27.36% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde IRMD op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.9%
Huidig dividendrendement40%
UitbetalingsratioBetaalt IRMD een betrouwbaar dividend?
Zie IRMD dividendgeschiedenis en benchmarks| IRADIMED dividenddata | |
|---|---|
| Ex Dividend Datum | May 15 2026 |
| Betaaldatum dividend | May 29 2026 |
| Dagen tot Ex-dividend | 7 days |
| Dagen tot dividendbetaaldatum | 7 days |
Betaalt IRMD een betrouwbaar dividend?
Zie IRMD dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 22:57 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
IRADIMED CORPORATION wordt gevolgd door 4 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |